# Type 1 Diabetes - Pathophysiology and Insulin Management

## Pathophysiology

### Autoimmune Beta-Cell Destruction

Type 1 diabetes results from the immune-mediated destruction of insulin-producing pancreatic beta cells within the islets of Langerhans. The overwhelming majority of cases, designated type 1A, are autoimmune in nature, accounting for more than 90% of type 1 diabetes. A smaller proportion, termed type 1B, involves idiopathic beta-cell failure without detectable autoimmune markers and is more commonly observed in individuals of African or Asian ancestry.

The destructive process is mediated primarily by autoreactive CD4+ and CD8+ T lymphocytes that target beta-cell-specific antigens. The histological hallmark is insulitis, a lymphocytic infiltration of the islets that progresses over a variable period of months to years, gradually depleting the beta-cell mass. Clinical diabetes manifests when approximately 80 to 90% of beta-cell mass has been destroyed, at which point endogenous insulin production becomes insufficient to maintain glucose homeostasis. Following diagnosis, many patients experience a "honeymoon period" lasting weeks to months, during which residual beta-cell function (reflected by detectable C-peptide levels) produces sufficient insulin to temporarily reduce exogenous insulin requirements. This period eventually resolves as the remaining beta cells succumb to ongoing autoimmune destruction.

### Autoantibodies

Several autoantibodies targeting beta-cell antigens serve as serological markers of the autoimmune process and are invaluable for diagnosis, risk stratification, and screening. Islet cell antibodies (ICA), the original marker identified by immunofluorescence, are now less commonly used. Glutamic acid decarboxylase antibodies (GADA or anti-GAD65) are the most commonly positive antibody in adults, present in 80 to 90%, and persist the longest of all autoantibodies. Insulinoma-associated antigen-2 antibodies (IA-2A) are present in 60 to 70% of patients. Insulin autoantibodies (IAA) are characteristically the first autoantibody to appear in young children, with their prevalence inversely correlated with age at diagnosis. Zinc transporter 8 antibodies (ZnT8A), present in 60 to 80% at diagnosis, add approximately 5% diagnostic sensitivity when other antibodies are negative.

The number of positive autoantibodies carries strong prognostic significance for disease progression. A single positive autoantibody confers approximately a 10 to 15% 10-year risk of developing clinical diabetes, while the presence of two or more autoantibodies predicts greater than 90% lifetime risk of progression to clinical disease.

### Staging of Type 1 Diabetes (2015 JDRF/ADA/Endocrine Society)

The recognition that type 1 diabetes progresses through identifiable presymptomatic stages has transformed prevention strategies. Stage 1 is defined by the presence of two or more autoantibodies with normoglycemia in a presymptomatic individual. Stage 2 is characterized by two or more autoantibodies with dysglycemia (impaired fasting glucose or impaired glucose tolerance) but still presymptomatic. Stage 3 represents clinical diabetes with hyperglycemia meeting standard diagnostic criteria and the onset of symptoms. This staging framework has become particularly relevant with the approval of disease-modifying therapies that can delay progression from stage 2 to stage 3.

### Genetic Susceptibility

The genetic basis of type 1 diabetes is dominated by the HLA complex on chromosome 6p21, which accounts for approximately 50% of the overall genetic risk. The highest risk genotype is the HLA-DR3/4-DQ2/8 heterozygous combination, which confers a lifetime risk of approximately 1 in 15 to 20. Conversely, HLA-DQ6 (DQB1*0602) is protective. Numerous non-HLA genes contribute to the remaining genetic risk, including the insulin gene variable number tandem repeat (INS VNTR), PTPN22, CTLA-4, IL2RA, and IFIH1. Concordance rates in monozygotic twins range from 30 to 70%, while dizygotic twin concordance is 6 to 10%, underscoring the substantial but incomplete role of genetics.

### Environmental Triggers

Environmental factors are believed to trigger the autoimmune process in genetically susceptible individuals. Viral infections, particularly enteroviruses (Coxsackie B), rotavirus, congenital rubella, and cytomegalovirus, have been implicated through molecular mimicry and bystander activation mechanisms. Dietary factors including early cow's milk exposure (though the TRIGR trial showed no definitive effect), gluten exposure, and vitamin D deficiency have been investigated. Alterations in the gut microbiome, specifically reduced bacterial diversity, have been observed to precede autoantibody development. The hygiene hypothesis proposes that reduced microbial exposure in developed nations may increase autoimmune susceptibility.

<image>A timeline diagram showing the natural history of type 1 diabetes. Starting from left: genetic susceptibility (HLA-DR3/4) plus environmental trigger leads to immune activation. Show a declining curve of beta-cell mass (y-axis) over time (x-axis, spanning months to years). Mark key stages: (1) appearance of first autoantibody, (2) Stage 1 - multiple autoantibodies with normal glucose shown as a green zone, (3) Stage 2 - dysglycemia with declining beta-cell mass shown as a yellow zone, (4) Stage 3 - clinical diabetes onset at ~10-20% remaining beta-cell mass shown as a red zone, (5) honeymoon period with slight recovery, (6) complete beta-cell destruction with absent C-peptide. Include a parallel track showing autoantibody profiles (GADA, IA-2A, IAA, ZnT8A) appearing over time. Use clean medical illustration style.</image>

## Disease-Modifying Therapy

### Teplizumab (Anti-CD3 Monoclonal Antibody)

Teplizumab, an anti-CD3 monoclonal antibody, received FDA approval in 2022 as the first disease-modifying therapy for type 1 diabetes, representing a paradigm shift in the field. It is indicated for delaying the onset of stage 3 type 1 diabetes in individuals aged 8 years and older who are at stage 2 (two or more autoantibodies with dysglycemia). The mechanism involves modulation of autoreactive T cells through partial T-cell exhaustion and expansion of regulatory T-cell populations.

The pivotal TN-10 trial demonstrated that a single 14-day intravenous infusion course delayed the median onset of stage 3 diabetes by approximately 2 years (48 versus 24 months), with some patients experiencing delays exceeding 5 years on longer follow-up. Side effects include expected transient lymphopenia, rash, headache, rare cytokine release syndrome, and an increased risk of infection during the lymphopenic period. The approval of teplizumab has made screening of at-risk individuals, particularly first-degree relatives of patients with type 1 diabetes, clinically actionable for the first time.

### Other Investigational Approaches

The search for additional disease-modifying therapies continues across multiple fronts. Verapamil showed preservation of C-peptide in the VERITAS trial in newly diagnosed type 1 diabetes, acting through inhibition of thioredoxin-interacting protein (TXNIP). Low-dose anti-thymocyte globulin (ATG) has demonstrated partial C-peptide preservation. Abatacept (CTLA-4 Ig) and rituximab (anti-CD20) have shown transient benefits in preserving beta-cell function but with waning effects over time. Islet transplantation has advanced significantly, with donislecel (allogeneic islet cell therapy) receiving FDA approval in 2023 for type 1 diabetes patients with severe hypoglycemia, building on the Edmonton protocol of islet infusion with immunosuppression. Stem cell-derived beta cells, exemplified by Vertex's VX-880 program, are in early clinical trials showing promising insulin independence.

## Diagnosis

### Diagnostic Criteria (ADA 2024)

The diagnosis of diabetes mellitus is established by any of the following criteria: fasting plasma glucose of 126 mg/dL (7.0 mmol/L) or above; 2-hour plasma glucose of 200 mg/dL (11.1 mmol/L) or above during a 75-gram oral glucose tolerance test; HbA1c of 6.5% (48 mmol/mol) or above; or random plasma glucose of 200 mg/dL or above with classic hyperglycemic symptoms. In asymptomatic patients, two abnormal tests are required for diagnosis, while a single test suffices if unequivocal hyperglycemia is accompanied by symptoms.

### Distinguishing T1D from T2D

The differentiation between type 1 and type 2 diabetes is essential for appropriate management. Type 1 diabetes typically presents acutely with polyuria, polydipsia, and weight loss developing over weeks, though it can present more insidiously in adults (LADA). C-peptide is low or undetectable in established type 1 diabetes (below 0.6 ng/mL fasting or below 1.8 ng/mL stimulated). Autoantibodies are positive, with GADA being the minimum recommended screen, supplemented by IA-2A and ZnT8A for additional sensitivity. DKA at presentation is more common in type 1 but can occur in type 2 (ketosis-prone diabetes). Normal or low BMI is typical in type 1 diabetes, though overweight or obesity does not exclude the diagnosis.

### LADA (Latent Autoimmune Diabetes in Adults)

Latent autoimmune diabetes in adults represents autoimmune diabetes presenting after age 30 with an initial non-insulin-dependent phase. The defining laboratory feature is GADA positivity. Patients initially may respond to oral agents for months to years before progressing to insulin dependence, typically within 1 to 6 years. Compared to true type 2 diabetes, LADA patients tend to have lower BMI and lower C-peptide levels. Sulfonylureas should be avoided as they may accelerate beta-cell failure, and insulin should be started when oral agents fail.

## Insulin Therapy

### Insulin Types and Pharmacokinetics

| Insulin Type | Examples | Onset | Peak | Duration | Key Notes |
|---|---|---|---|---|---|
| Ultra-rapid | Faster aspart (Fiasp), Ultra-rapid lispro (Lyumjev) | 5-15 min | 30-90 min | 3-5 h | Improved postprandial control |
| Rapid-acting | Lispro (Humalog), Aspart (NovoLog), Glulisine (Apidra) | 15-30 min | 1-2 h | 3-5 h | Standard prandial insulin |
| Inhaled | Afrezza | 12-15 min | 35-55 min | 1.5-3 h | CI in asthma/COPD; requires PFTs |
| Short-acting (Regular) | Humulin R, Novolin R | 30-60 min | 2-4 h | 6-8 h | IV use (DKA, perioperative); U-500 for resistance |
| Intermediate (NPH) | Humulin N, Novolin N | 1-2 h | 4-8 h (variable) | 12-16 h | Largely replaced; nocturnal hypo risk |
| Long-acting | Glargine U-100 (Lantus) | 1-2 h | Relatively peakless | 20-24 h | Once daily |
| | Glargine U-300 (Toujeo) | 1-2 h | Flat | Up to 36 h | Less nocturnal hypo than U-100 |
| | Detemir (Levemir) | 1-2 h | Slight peak 6-8 h | 12-20 h | Often requires BID dosing |
| Ultra-long | Degludec (Tresiba) | 1-2 h | Flattest | >42 h (t½ ~25 h) | Lowest hypo risk (SWITCH trials) |
| Weekly | Icodec (Awiqli) | — | Flat | ~1 week (t½ ~196 h) | FDA approved 2024; ONWARDS trials |

#### Rapid-Acting Insulins

Multiple rapid-acting insulin analogs are available, each with subtle differences in onset and peak timing. Insulin lispro (Humalog), insulin aspart (NovoLog), and insulin glulisine (Apidra) share similar pharmacokinetic profiles with onset at 15 to 30 minutes, peak at 1 to 2 hours, and duration of 3 to 5 hours. Ultra-rapid formulations provide faster onset: ultra-rapid lispro (Lyumjev, onset 10 to 15 minutes) and faster aspart (Fiasp, onset 5 to 10 minutes, enhanced by niacinamide and L-arginine excipients), offering improved postprandial glucose control. Inhaled insulin (Afrezza) provides ultra-rapid onset at 12 to 15 minutes with a peak at 35 to 55 minutes and a shorter duration of approximately 1.5 to 3 hours, but is contraindicated in asthma and COPD and requires baseline and periodic pulmonary function testing.

#### Short-Acting Insulin

Regular human insulin (Humulin R, Novolin R) has a slower onset of 30 to 60 minutes, peaks at 2 to 4 hours, and lasts 6 to 8 hours. It remains the standard for intravenous insulin infusions in DKA, perioperative management, and some pump protocols. A concentrated U-500 formulation is available for patients with severe insulin resistance.

#### Intermediate-Acting Insulin

NPH insulin (Humulin N, Novolin N), with onset at 1 to 2 hours, a variable peak at 4 to 8 hours, and duration of 12 to 16 hours, has been largely replaced by long-acting analogs due to its significant absorption variability and associated risk of nocturnal hypoglycemia.

#### Long-Acting/Basal Insulins

The long-acting basal insulin landscape has evolved substantially. Insulin glargine U-100 (Lantus) provides a relatively peakless profile over 20 to 24 hours. Insulin glargine U-300 (Toujeo), a more concentrated formulation, offers a flatter, more prolonged profile extending up to 36 hours with less nocturnal hypoglycemia. Insulin detemir (Levemir) has a duration of 12 to 20 hours through albumin binding and often requires twice-daily dosing. Insulin degludec (Tresiba) is an ultra-long-acting insulin with a half-life of approximately 25 hours and duration exceeding 42 hours, providing the flattest profile and lowest hypoglycemia risk among basal insulins, as demonstrated in the SWITCH 1 and 2 trials. The newest advance is insulin icodec (Awiqli), a once-weekly basal insulin with a half-life of approximately 196 hours that received FDA approval in 2024 and demonstrated non-inferiority to daily basal insulin in the ONWARDS clinical trial program.

<image>A pharmacokinetic comparison chart showing insulin action profiles over time. X-axis represents time in hours (0-36 hours), Y-axis represents relative insulin effect. Plot overlapping curves for: rapid-acting (lispro/aspart - sharp peak at 1-2h, gone by 5h), ultra-rapid (Fiasp/Lyumjev - even sharper earlier peak), regular insulin (broader peak at 2-4h), NPH (variable peak at 4-8h with wider curve), glargine U-100 (flat line from 2-24h), glargine U-300 (even flatter line from 2-30h), degludec (flattest line from 2-42h), and detemir (slight peak at 6-8h, 12-20h duration). Use different colors for each insulin with a clear legend. Shade the approximate injection-to-meal timing window for rapid-acting insulins. Use smooth curves with pharmacokinetic accuracy.</image>

### Basal-Bolus (Multiple Daily Injection) Regimen

#### Basal Insulin

Basal insulin provides approximately 40 to 50% of the total daily dose (TDD) and controls glucose between meals and overnight. The initial TDD is estimated at 0.4 to 0.6 units/kg/day, with lower doses during the honeymoon period and higher doses during puberty or illness. Basal dose titration proceeds by adjusting 1 to 2 units every 2 to 3 days, targeting fasting glucose of 70 to 130 mg/dL. The most common approach uses insulin degludec or glargine administered once daily.

#### Bolus (Prandial) Insulin

Bolus insulin with a rapid-acting analog is administered before each meal, typically requiring 3 to 4 injections daily. Two key parameters govern prandial dosing. The insulin-to-carbohydrate ratio (ICR) is estimated initially using the "rule of 500" (500 divided by TDD); for example, a TDD of 50 units yields an ICR of 1:10, meaning 1 unit of insulin covers 10 grams of carbohydrate. The correction or sensitivity factor (ISF) is estimated using the "rule of 1800" for rapid-acting insulin (1800 divided by TDD); with a TDD of 50 units, the ISF is 1:36, meaning 1 unit lowers glucose by approximately 36 mg/dL.

Pre-meal injection timing of 10 to 15 minutes before eating optimizes postprandial glucose control for rapid-acting insulins, with longer pre-bolus intervals recommended for high-carbohydrate meals or elevated pre-meal glucose. The dose calculation integrates both components: meal dose equals (carbohydrate grams divided by ICR) plus ((current blood glucose minus target blood glucose) divided by ISF) minus any insulin on board (IOB) from recent boluses. The post-meal glucose target is below 180 mg/dL at 2 hours.

### Insulin Dose Adjustments

Effective insulin management relies on pattern management, adjusting doses based on 3 or more days of consistent glucose patterns while changing only one variable at a time. Basal adequacy can be assessed by skipping a meal: if glucose rises by more than 30 mg/dL, basal insulin is insufficient, whereas a drop of more than 30 mg/dL indicates excessive basal dosing. ICR adjustments follow post-meal glucose trends, and ISF adjustments respond to the effectiveness of correction doses.

### Insulin Pump Therapy (CSII) - Overview

Continuous subcutaneous insulin infusion (CSII) via a programmable insulin pump delivers rapid-acting insulin as basal rates (programmed hourly with the ability to vary throughout the day) and bolus doses calculated using ICR and ISF programmed into the pump. Key advantages include flexible basal rates for phenomena like the dawn phenomenon, precise dosing in increments as small as 0.025 to 0.05 units, reduced glycemic variability, and fewer injections. Detailed coverage of insulin pump therapy and automated insulin delivery systems appears in the dedicated lecture on CGM and pump therapy.

## Glycemic Targets

### ADA Recommendations (2024)

The ADA glycemic targets for most adults with type 1 diabetes include an HbA1c below 7.0%, with tighter targets below 6.5% if achievable without significant hypoglycemia, and less stringent targets below 8.0% for those with hypoglycemia unawareness, limited life expectancy, or significant comorbidities. Pre-meal glucose targets are 80 to 130 mg/dL, with post-meal glucose below 180 mg/dL at 1 to 2 hours. CGM-derived metrics have become increasingly important: time in range (TIR) of greater than 70% in the 70 to 180 mg/dL range correlates with an HbA1c of approximately 7.0%, time below range (TBR) should be less than 4% below 70 mg/dL and less than 1% below 54 mg/dL, and time above range (TAR) should be less than 25% above 250 mg/dL.

### Key Landmark Trials

The Diabetes Control and Complications Trial (DCCT), published in 1993, established the foundational evidence for intensive insulin therapy in type 1 diabetes. Intensive therapy achieving an HbA1c of approximately 7.0% compared to conventional therapy at approximately 9.0% produced a 76% reduction in retinopathy risk, 60% reduction in neuropathy, and 54% reduction in microalbuminuria, though at the cost of a 3-fold increase in severe hypoglycemia. The EDIC study, the long-term follow-up of the DCCT cohort, demonstrated the concept of "metabolic memory" or the "legacy effect": the intensive therapy group continued to show lower rates of cardiovascular events (42% reduction) and microvascular complications decades later, even after HbA1c levels converged between the two groups.

## Hypoglycemia Management

### Classification

| Level | Glucose | Definition | Action |
|---|---|---|---|
| Level 1 (Alert) | 54-70 mg/dL | Alert value | Fast-acting carbohydrates (15-20 g); recheck in 15 min |
| Level 2 (Clinically significant) | <54 mg/dL | Clinically significant hypoglycemia | Immediate treatment with fast-acting glucose |
| Level 3 (Severe) | Any | Requires assistance from another person | Glucagon (IM 1 mg, nasal 3 mg, or dasiglucagon 0.6 mg SC); IV D50 25 mL in hospital |

Hypoglycemia is classified into three levels based on severity. Level 1 is a glucose alert value of 54 to 70 mg/dL requiring treatment with fast-acting carbohydrates. Level 2 is clinically significant hypoglycemia below 54 mg/dL requiring immediate treatment. Level 3 is severe hypoglycemia requiring assistance from another person regardless of the measured glucose value.

### Impaired Awareness of Hypoglycemia (IAH)

Impaired awareness of hypoglycemia affects 20 to 25% of patients with type 1 diabetes and is strongly associated with recurrent hypoglycemia. The mechanism involves the phenomenon of hypoglycemia-associated autonomic failure (HAAF), in which repeated hypoglycemic episodes progressively shift the adrenergic response threshold to lower glucose levels, blunting the warning symptoms that normally prompt corrective action. Assessment can be performed using the Clarke or Gold questionnaires. The most effective treatment is strict hypoglycemia avoidance for 2 to 4 weeks, which can restore awareness in many patients. CGM technology is invaluable in this setting, and insulin pump therapy with automated insulin delivery provides an additional protective mechanism.

### Treatment of Hypoglycemia

For mild to moderate hypoglycemia in a conscious patient, the "rule of 15" is applied: 15 to 20 grams of fast-acting glucose (glucose tablets, juice, or regular soda) is consumed, blood glucose is rechecked in 15 minutes, and the treatment is repeated if glucose remains below 70 mg/dL. For severe hypoglycemia in an unconscious patient or one unable to self-treat, several rescue options are available: intramuscular or subcutaneous glucagon injection (1 mg from a traditional kit), intranasal glucagon (Baqsimi, 3 mg as a single nasal spray), dasiglucagon (Zegalogue, 0.6 mg subcutaneously, with the advantage of room-temperature stability), or intravenous dextrose (25 mL of D50, providing 12.5 grams of dextrose) in the hospital setting.

## Complication Screening

### Microvascular Complications

Screening for microvascular complications in type 1 diabetes follows established timelines. Retinopathy screening with a dilated eye examination begins annually starting 5 years after diagnosis (or at puberty in pediatric patients), with earlier screening if glycemic control has been poor. Nephropathy screening with annual urine albumin-to-creatinine ratio (UACR) and serum creatinine with eGFR begins 5 years after diagnosis, with ACE inhibitors or ARBs initiated for persistent albuminuria. Neuropathy screening with an annual foot examination including monofilament testing, vibration assessment, and ankle reflexes begins 5 years after diagnosis.

### Macrovascular Complications

Cardiovascular risk assessment should be performed, with statin therapy initiated per ADA guidelines based on age, risk factors, and disease duration. The blood pressure target is below 130/80 mmHg. Aspirin is not routinely recommended for primary prevention in type 1 diabetes without additional cardiovascular disease risk factors.

### Associated Autoimmune Conditions

Type 1 diabetes clusters with other autoimmune conditions that require screening. Celiac disease, with a prevalence of 5 to 10% in type 1 diabetes, should be screened at diagnosis and if symptoms develop, using tissue transglutaminase IgA. Thyroid disease should be screened with TSH at diagnosis and annually, as 15 to 30% of patients develop autoimmune thyroid disease. Addison disease, while less common, should be suspected if symptoms suggest adrenal insufficiency. Pernicious anemia and vitiligo are additional associations.

## Key Clinical Pearls

- Teplizumab represents a paradigm shift as the first disease-modifying therapy for presymptomatic T1D; screening at-risk individuals (first-degree relatives) with autoantibodies is now actionable
- The "rule of 500" for ICR and "rule of 1800" for ISF are starting estimates only; individual titration based on glucose data is essential
- Honeymoon period insulin requirements may drop dramatically (to <0.3 units/kg/day); maintain low-dose insulin to preserve residual beta-cell function
- DCCT/EDIC demonstrated that early intensive therapy produces a "legacy effect" that protects against complications for decades; optimal control matters most in early disease
- Insulin degludec has the flattest basal profile and lowest hypoglycemia risk among basal insulins; consider for patients with frequent nocturnal hypoglycemia or hypoglycemia unawareness
- Always screen for celiac disease and thyroid disease at T1D diagnosis; these autoimmune conditions cluster and can significantly affect glycemic control if missed

## References

1. Atkinson MA, et al. "Type 1 Diabetes." Lancet. 2014;383(9911):69-82.
2. The DCCT Research Group. "The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications." N Engl J Med. 1993;329(14):977-986.
3. Herold KC, et al. "An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes." N Engl J Med. 2019;381(7):603-613.
4. ElSayed NA, et al. "Standards of Care in Diabetes - 2024." Diabetes Care. 2024;47(Supplement_1):S1-S321.
5. Holt RIG, et al. "The Management of Type 1 Diabetes in Adults. A Consensus Report by ADA and EASD." Diabetes Care. 2021;44(11):2589-2625.